Minor adverse events · sexually active adults
It is very uncertain whether macrolide (erythromycin) changes minor adverse events compared with any other macrolide (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resolution of symptoms post‐treatment (ITT analysis) · group A streptococcal pharyngitis
Macrolides showed no clear difference in resolution of symptoms post‐treatment (ITT analysis) compared with penicillin (low certainty).
1 finding from 1 review
Resolution of symptoms post‐treatment (evaluable participants) · group A streptococcal pharyngitis
Macrolides showed no clear difference in resolution of symptoms post‐treatment (evaluable participants) compared with penicillin (low certainty).
1 finding from 1 review
Relapse · group A streptococcal pharyngitis
Macrolides showed no clear difference in incidence of relapse (evaluable participants) compared with penicillin (low certainty).
1 finding from 1 review
Adverse events (ITT analysis) · group A streptococcal pharyngitis
Macrolides showed no clear difference in adverse events (ITT analysis) compared with penicillin (low certainty).
1 finding from 1 review
Serious adverse events · adults and adolescents with scrub typhus
1 finding from 1 review
Treatment failure · adults and adolescents with scrub typhus
It is very uncertain whether macrolides changes treatment failure compared with doxycycline (very low certainty).
1 finding from 1 review
Resolution of fever within 48 hours · adults and adolescents with scrub typhus
It is very uncertain whether macrolides changes resolution of fever within 48 hours compared with doxycycline (very low certainty).
1 finding from 1 review
Resolution of fever within 5 days · adults and adolescents with scrub typhus
Macrolides showed no clear difference in resolution of fever within 5 days compared with doxycycline (low certainty).
1 finding from 1 review
Time to defervescence · adults and adolescents with scrub typhus
1 finding from 1 review
Quality of life, measured by CRQ (dyspnoea, fatigue, emotional function, and mastery subscales) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Deaths · any indication
Other adverse events in people taking macrolide antibiotics showed no clear difference in deaths compared with placebo (low certainty).
1 finding from 1 review
Cardiac disorders · any indication
It is very uncertain whether other adverse events in people taking macrolide antibiotics changes cardiac disorders compared with placebo (very low certainty).
1 finding from 1 review
Hearing loss · any indication
Other adverse events in people taking macrolide antibiotics showed no clear difference in hearing loss compared with placebo (low certainty).
1 finding from 1 review